Aquestive Therapeutics
(NASDAQ:AQST)
$4.34
0.06[1.40%]
At close: Apr 23
$4.34
0[0.00%]
After Hours: 7:58PM EDT

Aquestive Therapeutics Stock (NASDAQ:AQST), Guidance and Forecast

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.

Date Announced
ticker
Company Name
Period
Period Year
Min EPS
Max EPS
Estimate
Min Rev
Max Rev
Revenue Estimate
Get Alert
03/05/2024AQST
Aquestive Therapeutics
FY2024$48.00M$51.00M$48.10MGet Alert
11/06/2023AQST
Aquestive Therapeutics
FY2023$47.00M$50.00M$47.45MGet Alert
08/07/2023AQST
Aquestive Therapeutics
FY2023$44.00M$48.00M$43.37MGet Alert
05/02/2023AQST
Aquestive Therapeutics
FY2023$42.00M$46.00M$39.06MGet Alert
03/07/2023AQST
Aquestive Therapeutics
FY2023$37.00M$41.00M$37.83MGet Alert
11/01/2022AQST
Aquestive Therapeutics
FY2022$46.00M$49.00M$47.01MGet Alert
08/02/2022AQST
Aquestive Therapeutics
FY2022$46.00M$49.00M$46.46MGet Alert
05/03/2022AQST
Aquestive Therapeutics
FY2022$42.00M$47.00M$48.01MGet Alert
03/08/2022AQST
Aquestive Therapeutics
FY2022$42.00M$47.00M$62.68MGet Alert
11/02/2021AQST
Aquestive Therapeutics
FY2021$47.00M$49.00M$48.32MGet Alert
08/03/2021AQST
Aquestive Therapeutics
FY2021$46.00M$48.00M$40.07MGet Alert
05/04/2021AQST
Aquestive Therapeutics
FY2021$38.00M$42.00M$39.13MGet Alert
03/09/2021AQST
Aquestive Therapeutics
FY2021$38.00M$42.00M$41.19MGet Alert
11/04/2020AQST
Aquestive Therapeutics
FY2020$42.00M$46.00M$47.32MGet Alert
08/04/2020AQST
Aquestive Therapeutics
FY2020$35.00M$45.00M$38.42MGet Alert
05/05/2020AQST
Aquestive Therapeutics
FY2020$35.00M$45.00M$41.40MGet Alert
03/11/2020AQST
Aquestive Therapeutics
FY2020$35.00M$45.00M$43.86MGet Alert
01/10/2020AQST
Aquestive Therapeutics
FY2020$35.00M$45.00M$56.85MGet Alert
01/10/2020AQST
Aquestive Therapeutics
FY2019$52.00M$52.00M$46.36MGet Alert

FAQ

Q

What is the most recent guidance for Aquestive Therapeutics (AQST)?

A

There have been no specific sales or earnings guidance reported for Aquestive Therapeutics in recent months.

Browse guidance and forecast on all stocks.

People Also Watch